White light cystoscopy (“WLC”) is the most commonly used procedure to detect non-muscle invasive bladder cancer (“NMIBC”) Despite its prevalence, WLC is not the most effective method and contributes to a high bladder cancer recurrence rate Blue light cystoscopy (“BLC”) is a more recent and highly effective method, but the high cost of equipment and … Continue reading “Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Revolutionary Technology a Cost Saver for Hospitals and Patients”
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed a product that deals with the challenges associated with both blue light and white light cystoscopies. Clinical data support the value of blue light cystoscopy in detecting bladder cancer. Despite this fact, “the technology is used in less than 10% of such procedures … Continue reading “NetworkNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Solution Solves Cystoscopy Challenges”
Imagin Medical has developed a technology, currently entering the manufacturing stage, which it believes will revolutionize bladder cancer surgical imaging The company’s technology, the i/Blue Imaging System, can display blue and white light images of the bladder side-by-side simultaneously, allowing surgeons greater ability to detect and remove tumors Imagin has raised a $2.165 million convertible … Continue reading “Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Takes Bladder Cancer Battle to Next Level”
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is engaged in establishing a new standard for the visualization of cancer during minimally invasive surgeries (“MIS”). The company is currently focused on bladder cancer, the most expensive cancer to treat due to a high 50% recurrence rate that leaves approximately 600,000 U.S. patients living … Continue reading “NetworkNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Bringing Effective Solutions to Vast Market”
Archaic technology contributes to dismal recurrence rate in bladder cancer Imagin Medical revolutionizes the way surgeons can visualize cancer to better identify, and remove during surgery There is potential to extend this technology to virtually other endoscopic procedures The battle against cancer is too often set back by crushing blows of recurrence. The disease is … Continue reading “Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Reimagines Technology to Create Better Cancer Outcomes”
Imagin Medical Inc.’s patented i/Blue System revolutionizes the way surgeons are able to visualize the bladder and identify cancers during surgery The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies Bladder cystoscopies first target – multiple other endoscopic procedures planned Science and technology have continued … Continue reading “Better Cancer Outcomes Possible with Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology”
Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is focused on changing the standards of visualizing cancer during minimally invasive procedures. The company’s innovative technology has the potential to revolutionize the current standard of care for bladder cancer patients. Imagin Medical’s i/Blue Imaging(TM) System is based on advanced optics and light sensors and … Continue reading “NetworkNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging(TM) Technology Holds Potential Across Multiple Endoscopic Procedures”
Imagin Medical Inc. announced that it has now raised $2.165 million of the recent its convertible note offering The closing of the latest funding tranche will support the company’s progress toward the commercialization of its revolutionary bladder cancer visualization technology once final FDA approval is granted With better viewing options, the technology is designed to … Continue reading “Convertible Note Progress Brings Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Closer to Commercialization of New Surgical Tech”
Imagin Medical (CSE: IME) (OTC: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced that, further to its press releases of Oct. 22 and Nov. 10, 2020, it has closed the second tranche in the amount of US$1,415,500 of the convertible note … Continue reading “NetworkNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTC: IMEXF) Announces Closing of 2nd Tranche of Convertible Note Offering”
Imagin Medical Inc. is a surgical imaging company helping to advance the use of blue light cystoscopy (“BLC”) in battling bladder cancer and reducing costs associated with these procedures Bladder cancer is the sixth most prevalent cancer in the United States, and the third most common in men, yet the most expensive to treat While … Continue reading “Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Improving the Odds in Fighting Bladder Cancers”
